N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=85 An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
Overactive Bladder
Primary: Average Number of Voids Per Day — NA; NA Average Number of Voids
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
Phase 4 N=181 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale
N/A N=187 PCORI Urea Cycle Disorder Study
Urea Cycle Disorders
Primary: Mortality — 18.4; 20.7 participant per 1000 person-years
N/A N=40 Recovery of Bladder and Sexual Function After Spinal Cord Injury
Spinal Cord Injuries
Primary: Bladder Storage — 278.5; 447.75; 580.5; 313.0 mLH2O
N/A N=1,658 Prevention of Urinary Stones With Hydration
Urinary Stones
Primary: Number of Participants With a Symptomatic Stone Event — 154; 165 Participants
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
Phase 4 N=42 Validation of a Real-time Urodynamic Measure of Urinary Urgency
Overactive Bladder Syndrome
Primary: Change in Maximal Cystometric Capacity (mL) — 95; 473.50 milliliters (mL) — p=.005
N/A N=12 Uroflow Measurements in Healthy Volunteers
Healthy
Primary: Voided Volume — 306 mL
N/A N=56 Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05
Phase 4 N=28 Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g
N/A N=27 The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
Overactive Bladder
Primary: Change in the Relative Abundance of Lactobacillus — 0.143 proportion of total microbes
N/A N=20 Evaluation of a Novel Electronic Urine Output Monitor (eUOM)
Oliguria · Polyuria
Primary: Urine Output of SOC Device Versus Accuryn — 0; 5 Patients with airlocks
N/A N=154 PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
Overactive Bladder
Primary: Change in Number of Urinary Urge Incontinence (UUI) Episodes Per Day After the 12th PTNM Therapy Sessions From Baseline — -2.4 UUI episodes per day — p=<0.0001
N/A N=139 Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women
Recurrent Urinary Tract Infection in Adult Women
Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…
Phase 2 N=134 Bacterial Genomic Sequencing in Overactive Bladder
Overactive Bladder
Primary: Bacterial Genomic Sequencing — 25; 11; 3; 6 participants
N/A N=21 Comparative Urine Proteomic Studies of Overactive Bladder in Humans
Overactive Bladder
Primary: Bladder Diary to Assess Urinary Frequency at Baseline and at End of 6-week Treatment — 12.32; 10.79 urinations/day — p=0.19
Phase 4 N=20 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary Incontinence · Urgency Urinary
Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
Phase 2 N=7 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .286 Adverse Events — p==0.351
N/A N=11 Brain Targets in Patients With Bladder Emptying Difficulties
Neurogenic Bladder · Multiple Sclerosis · Voiding Dysfunction
Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05
Phase 2 N=222 Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax) — -1.69; -7.84; -6.69 cmH2O
Phase 3 N=104 The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Disorder of Urinary Stent
Primary: Lower Urinary Tract Symptoms (LUTS) — 11.12; 4.39; 7.21; 5.58 units on a scale
Phase 4 N=168 Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
Urgency Urinary Incontinence
Primary: Responder (Yes/no) — 23; 39; 36; 17 Participants
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
N/A N=108 Trial Assessing Renal Damage During Ureteroscopy
Nephrolithiasis
Primary: Change in Kidney Injury Molecule-1 (KIM-1) — 0.01077; 0.01228; 0.0246; 0.02413 ng/ml